SCHEMBL5260472

SCHEMBL5260472

NC(=O)/C(=C\c1c[nH]c2nc(NC(=O)c3cccc(N)c3)ccc12)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GRM5 P41594 1/20 0.39
ULK1 O75385 1/20 0.39
HDAC1 Q13547 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HSD17B10 Q99714 1/20 0.37
ALDH1A1 P00352 2/20 0.36
KDM4C Q9H3R0 1/20 0.36
KDM4E B2RXH2 1/20 0.36
KDR P35968 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
PTGS1 P23219 1/20 0.35
ADORA2A P29274 1/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
GFER P55789 1/20 0.35
PBRM1 Q86U86 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5260479 1.00 MEN1 (0.39) MEN1KMT2AGRM5ULK1HDAC1
SCHEMBL5262515 0.93 MEN1 (0.40) MEN1KMT2AGRM5ULK1HDAC1
SCHEMBL5262510 0.93 MEN1 (0.40) MEN1KMT2AGRM5ULK1HDAC1
SCHEMBL5263355 0.91 KMT2A (0.45) MEN1KMT2AGRM5NPC1RAB9A
SCHEMBL5262013 0.91 KMT2A (0.45) MEN1KMT2AGRM5NPC1RAB9A
SCHEMBL5260183 0.90 KMT2A (0.39) MEN1KMT2AGRM5ALDH1A1KDM4E
SCHEMBL5260182 0.90 KMT2A (0.39) MEN1KMT2AGRM5ALDH1A1KDM4E
SCHEMBL5259151 0.86 GLS (0.39) MEN1KMT2ANPC1RAB9AADORA2A
SCHEMBL5259144 0.86 GLS (0.39) MEN1KMT2ANPC1RAB9AADORA2A
SCHEMBL5260838 0.86 GRM5 (0.44) MEN1KMT2AGRM5SMN1; SMN2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1309590-B1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-09-19 EP claimed
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN (IT) 2003-01-02 US claimed
US-6335342-B1 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2002-01-01 US claimed
EP-1309590-B1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-09-19 EP disclosed
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN (IT) 2003-01-02 US disclosed
US-6486322-B1 Azaindole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA ITALIA S.P.A. (IT) 2002-11-26 US disclosed
US-6335342-B1 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2002-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS FFAR4, AZI2, CNKSR1 MEN1 3262/4885KMT2A 1011/4885GRM5 1930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.